Henry Ogbeifun, Corbyn M Gilmore, Zohra I Nooruddin, Supreet Kaur, Cynthia L Nguyen, Adriana Vargus, Jim Koeller, Dan F Smelter, Chengwen Teng, Kathleen Franklin, Xavier F Jones, Christopher R Frei
{"title":"Treatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study.","authors":"Henry Ogbeifun, Corbyn M Gilmore, Zohra I Nooruddin, Supreet Kaur, Cynthia L Nguyen, Adriana Vargus, Jim Koeller, Dan F Smelter, Chengwen Teng, Kathleen Franklin, Xavier F Jones, Christopher R Frei","doi":"10.1177/10781552261502428","DOIUrl":"https://doi.org/10.1177/10781552261502428","url":null,"abstract":"<p><p>IntroductionMantle cell lymphoma (MCL) is a rare subtype (5%) of Non-Hodgkin Lymphoma (NHL), with 5-year survival of about 50%. Bruton Tyrosine Kinase inhibitors (BTKis) may improve health outcomes for patients with relapsed or refractory (R/R) MCL.Study objectiveThe objective of this study was to compare treatment patterns and healthcare utilization for patients with R/R MCL prescribed their first BTKi therapy using data from the national Veterans Health Administration (VHA).MethodsThis was a retrospective cohort study of adult patients (18 + years) prescribed BTKis for MCL in all VHA medical facilities in the United States from 1/1/20 to 12/31/23. Data were statistically analyzed using chi-square, Wilcoxon Rank-Sum test, Kaplan-Meier (KM) curves, multivariable negative binomial regression, and Cox Proportional Hazards regression, and a p-value <0.05.ResultsThere were 494 patients included. Of those included, 177 received ibrutinib, 189 received acalabrutinib, and 128 received zanubrutinib. More patients on ibrutinib switched to other BTKis (27%) compared to patients on acalabrutinib (10%, p < 0.01) or zanubrutinib (9%, p < 0.01). Median (interquartile range [IQR]) laboratory visits at 12 months were higher for ibrutinib (5, 0-12) than acalabrutinib (1, 0-8, p < 0.01) or zanubrutinib (0, 0-6, p < 0.01). Finally, overall survival (OS) was higher for patients on zanubrutinib than those on ibrutinib (p < 0.01) or acalabrutinib (p < 0.01).ConclusionsPatients prescribed acalabrutinib and zanubrutinib experienced fewer laboratory and hematology/oncology visits at 12 months than patients who received ibrutinib. Patients who received zanubrutinib experienced a survival advantage when compared to those treated with ibrutinib.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261502428"},"PeriodicalIF":1.3,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bispecific T-cell engagers beyond hematology: Expanding uses in solid tumors.","authors":"Kristen Rychalsky, Darren Luon, Joseph Tracchia","doi":"10.1177/10781552261500125","DOIUrl":"https://doi.org/10.1177/10781552261500125","url":null,"abstract":"<p><p>ObjectiveTo review the mechanism of action, clinical efficacy, safety considerations and future development of bispecific T-cell engagers (BTCEs) in solid tumors.Data sourcesA literature search was conducted using PubMed for clinical trials leading to FDA approvals and major oncology conference proceedings through February 2026. Major ongoing clinical trials were identified through a search of clinicaltrials.gov. Search terms included \"bispecific T-cell engager,\" \"BiTE,\" \"solid tumors,\" \"tarlatamab,\" and \"tebentafusp.\" Prescribing information was also evaluated.Data summaryBTCEs are antibodies designed to redirect cytotoxic T-cells toward tumor cells through binding of CD3 and tumor-associated antigens. FDA approvals of tebentafusp for HLA-A*02:01-positive metastatic uveal melanoma and tarlatamab for extensive stage small cell lung cancer have established utility of BTCE therapy in solid malignancies, with improved outcomes over conventional chemotherapy and immunotherapy. BTCEs have unique toxicities, such as cytokine release syndrome, that must be monitored and treated appropriately. Ongoing investigations are evaluating novel targets, optimized molecular constructs to overcome development challenges, including toxicity and tumor microenvironment barriers, as well as combination treatment strategies to improve the efficacy of BTCEs in solid tumors.ConclusionsTebentafusp and tarlatamab have established proof of concept for BTCE therapy in solid tumors, bridging the gap from hematologic malignancies. This class of therapy represents a promising platform for expanding applications across tumor types. Continued advances in target selection and strategies to overcome the tumor microenvironment and T-cell evasion barriers are expected to further expand the role of BTCEs in solid tumors.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261500125"},"PeriodicalIF":1.3,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cost-effectiveness of zenocutuzumab-zbco across three NRG1 fusion-positive indications.","authors":"Glen J Weiss","doi":"10.1177/10781552261496856","DOIUrl":"https://doi.org/10.1177/10781552261496856","url":null,"abstract":"<p><p>IntroductionZenocutuzumab-zbco is the first approved therapy for NRG1 fusion-positive cancer, indicated for non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma (CCA). At the pivotal analyses, overall survival (OS) was unreported for NSCLC and PDAC, whereas a later publication reported observed OS and progression-free survival (PFS) for CCA. Cost-effectiveness was evaluated from a US payer perspective.MethodsA three-state partitioned survival model estimated incremental costs and quality-adjusted life-years (QALYs) over 5 years. For NSCLC and PDAC, OS was modeled as a threshold variable across prespecified scenarios, with an incremental cost-effectiveness ratio (ICER) per scenario. For CCA, OS and PFS were reconstructed from published Kaplan-Meier curves and used directly, with a base-case ICER and extrapolation sensitivity. The wholesale acquisition cost was $24,155.46/infusion. Probabilistic, one-way, and threshold analyses were performed.ResultsFor NSCLC and PDAC, ICERs ranged from approximately $665,000 (PDAC, OS 18 months) to $2.79 million per QALY (NSCLC, OS 10 months). For CCA, using observed data, the base-case ICER was approximately $397,000 per QALY (extrapolation range $349,000-$430,000). No indication was cost-effective at $150,000 or $200,000 per QALY. Drug acquisition cost, comparator OS, and utilities were the dominant drivers. Cost-effectiveness required acquisition-cost reductions of 60% to 91%.ConclusionsAt its current price, zenocutuzumab is not cost-effective for any approved indication, whether OS is unobserved (NSCLC, PDAC) or observed (CCA). Cost-effectiveness is achievable only through substantial price reduction. NSCLC and PDAC findings are conditional on the prespecified OS scenarios; CCA findings rest on observed survival with extrapolation.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261496856"},"PeriodicalIF":1.3,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence in breast cancer pharmacotherapy: Treatment optimization, medication safety, and the evolving role of oncology pharmacists.","authors":"Anhar Adel Abdulla Abuzaid","doi":"10.1177/10781552261498674","DOIUrl":"https://doi.org/10.1177/10781552261498674","url":null,"abstract":"<p><p>ObjectiveTo critically review current evidence on artificial intelligence (AI) in breast cancer pharmacotherapy, emphasizing treatment optimization, treatment-response prediction, toxicity, medication safety, pharmacovigilance, clinical decision support, and the evolving role of oncology pharmacists.Data SourcesA structured narrative search used PubMed/MEDLINE as the principal database, supplemented by Google Scholar, citation tracking, and reference-list screening. The final PubMed search was executed on September 20, 2026, using a publication cutoff of September 14, 2026, corresponding to the date of the editorial decision, and identified 764 records. The six-day interval reflects the timing of the search rerun after the publication cutoff; publications after September 14 were not included. Evidence relevant to AI-supported breast cancer pharmacotherapy and oncology pharmacy practice was prioritized.Data SummaryAI applications include treatment-response prediction, clinical decision support, treatment stratification, toxicity prediction, and pharmacovigilance. Machine-learning models have addressed severe treatment-related toxicity, febrile neutropenia, and cardiotoxicity, while AI-based pharmacovigilance may support detection of adverse-event and polypharmacy patterns. However, much of the evidence remains retrospective or focused on technical performance rather than demonstrated improvement in patient-centered outcomes. Direct prospective evidence evaluating AI-integrated oncology pharmacist interventions remains limited.ConclusionsAI applications in breast cancer pharmacotherapy show promising technical and, in selected settings, clinical evidence, but evidence maturity varies substantially across applications. Direct prospective evidence demonstrating additional clinical benefit from integrated AI-oncology pharmacist interventions remains limited. Pharmacist-in-the-loop approaches should therefore be regarded as conceptual and testable models rather than established standards of care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498674"},"PeriodicalIF":1.3,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyun Woo Sam Jang, James Godin, Megan Rolle, Alfredo De la Torre, Darrell White, Laura V Minard
{"title":"Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, Canada.","authors":"Hyun Woo Sam Jang, James Godin, Megan Rolle, Alfredo De la Torre, Darrell White, Laura V Minard","doi":"10.1177/10781552261500471","DOIUrl":"https://doi.org/10.1177/10781552261500471","url":null,"abstract":"<p><p>IntroductionThis study aimed to characterize the incidence, grade, onset, duration and management of infusion-related reactions (IRRs) in patients receiving their first cycle of subcutaneous daratumumab and to evaluate the duration of the observation period.MethodsThis retrospective observational study included adult patients diagnosed with MM or AL amyloidosis who received their first cycle of subcutaneous daratumumab in Nova Scotia, Canada, between October 2021 and April 2025.ResultsSix IRRs were identified in 5 out of 140 patients (3.6%); 5 of the 6 reactions were categorized as low-grade and one patient developed grade 3 hypoxia which was managed with supplemental oxygen and diphenhydramine. The median time to IRR onset was 49.5 min (range 2-245) and the median time to resolution after intervention was 73.5 min (range 10-101). The IRR rate in patients who received 20 mg of dexamethasone or less was 5.8% versus 0% in patients who received greater than 20 mg.ConclusionsThis real-world analysis of patients receiving subcutaneous daratumumab for the first time revealed a low rate of IRRs and fewer IRRs in patients who received higher doses of dexamethasone prior to treatment. These findings suggest an important role for dexamethasone in IRR prophylaxis and support a reduction in the duration of the observation period post-subcutaneous daratumumab. Based on these results, the duration of the observation period in Nova Scotia was reduced from 4 h to 1 h, which saves chair time and has implications for cost savings, and the patient experience.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261500471"},"PeriodicalIF":1.3,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Use of an abridged desensitization protocol to rechallenge oxaliplatin dosing after a suspected hypersensitivity reaction to FOLFOX: A case report.","authors":"Grace Wong, Karen Mulder","doi":"10.1177/10781552261499384","DOIUrl":"https://doi.org/10.1177/10781552261499384","url":null,"abstract":"<p><p>IntroductionHypersensitivity reactions (HSRs) can occur in a consequential number of patients who receive oxaliplatin, a cornerstone agent of many chemotherapy regimens used to treat gastrointestinal malignancies. Premedications are not an infallible strategy for preventing HSR recurrence; thus, HSRs often preclude further treatment with this medication.Case reportWe present the case of an adult male who experienced clinical HSR symptoms (including rash, tachycardia and dyspnea) after receiving FOLFOX chemotherapy for adjuvant colon adenocarcinoma, and his subsequent clinical management.Management & outcomeTo facilitate further treatment with FOLFOX, an abridged desensitization protocol was implemented. The patient received one cycle of treatment as an inpatient and ensuing cycles as an outpatient successfully, until the end of his planned course.DiscussionOur patient case demonstrates potential feasibility of rechallenging oxaliplatin use following suspected HSRs in a combined inpatient and outpatient setting in Canada.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261499384"},"PeriodicalIF":1.3,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and hospital pharmacy implications of extended beyond-use dating for intravenous anticancer and supportive care admixtures: A systematic review and meta-analysis.","authors":"Sadaf Hameed, Asma Zafar","doi":"10.1177/10781552261498052","DOIUrl":"https://doi.org/10.1177/10781552261498052","url":null,"abstract":"<p><p>IntroductionThe stability of intravenous drug admixtures is essential for ensuring safety, efficacy, and efficient resource utilization in clinical practice. This systematic review and meta-analysis evaluated the physicochemical stability of intravenous anticancer and supportive-care admixtures and examined the influence of drug class, storage temperature, light exposure, container type, and diluent selection.MethodsThe review followed PRISMA 2020 guidelines and was registered with PROSPERO (CRD420261368183). Thirty-three studies were included. Random-effects models were used to estimate pooled stability durations, with subgroup analyses, meta-regression, and risk-of-bias assessment across six domains.ResultsThe pooled mean maximum stability duration was 30.7 days (95% CI 20.1-41.3; prediction interval 1.4-60.0 days), with extreme heterogeneity (I<sup>2</sup> = 99.7%), limiting generalizability. Monoclonal antibodies generally showed longer stability than cytotoxic agents, particularly under refrigeration. Refrigeration was associated with modestly longer stability, while light exposure appeared to reduce stability, although evidence was limited. Container and diluent effects were variable and drug dependent. Only 12.1% of studies included microbiological assessment, and overall study quality was moderate.ConclusionsIntravenous drug admixtures may remain physicochemically stable beyond manufacturer-defined beyond-use dates under controlled conditions. However, extended beyond-use dating should not be based on physicochemical evidence alone. Drug-specific assessment, sterility assurance, and preferably local validation are required before implementation in hospital pharmacy practice.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261498052"},"PeriodicalIF":1.3,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of a machine learning-based risk warning model for potentially inappropriate medication use among older patients in a hematology service.","authors":"Aslınur Albayrak, Başak Firdevs Dilara Tokgöz, Demircan Özbalcı","doi":"10.1177/10781552261499304","DOIUrl":"https://doi.org/10.1177/10781552261499304","url":null,"abstract":"<p><p>IntroductionOlder hematology patients often have multiple comorbidities and receive complex medication therapies; this can increase the risk of potentially inappropriate medication (PIM) use. A machine learning model could potentially serve as an automated screening and warning tool to facilitate the identification of PIM and support timely medication review in these patients. The aim of this study is to develop machine learning-based model that provide warnings regarding PIMs use in elderly patients hospitalized in the hematology service.MethodsThis retrospective pilot study was conducted on patients over 65 years of age who were admitted to the hematology service of a university hospital in Türkiye between 2018 and 2020. PIMs were determined according to the American Geriatrics Association's 2023 Beers Criteria. Python (v3.12.7) was used for data analysis in this study. The stratified 5-fold cross-validation method was used. To estimate PIM, seven different classification algorithms were used. Model performance was compared using accuracy, precision, recall, F1 score, receiver operating characteristics (ROC) curve, and area under the curve (AUC), brier score evaluation parameters.ResultsThis study included 190 patients. 45.8% of patients had PIM. The logistic regression model demonstrated the highest performance with 0.87 accuracy, 0.83 recall, 0.86 F1 score, and 0.91 AUC.ConclusionThe logistic regression model was determined to be the best-performing model. The developed patient-based automated screening model is promising and can be considered a reliable early warning mechanism for clinical pharmacists and physicians.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261499304"},"PeriodicalIF":1.3,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sandra García-Contreras, María Remedios Marqués-Miñana, Virginia Bosó-Ribelles, Carolina Fuentes-Socorro, Paloma Escobar-Cava, Javier García-Pellicer, José Luis Poveda-Andrés
{"title":"Author response to the Letter to the Editor: \"Model informed precision dosing for most accurate busulfan therapeutic drug monitoring\".","authors":"Sandra García-Contreras, María Remedios Marqués-Miñana, Virginia Bosó-Ribelles, Carolina Fuentes-Socorro, Paloma Escobar-Cava, Javier García-Pellicer, José Luis Poveda-Andrés","doi":"10.1177/10781552261499517","DOIUrl":"https://doi.org/10.1177/10781552261499517","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261499517"},"PeriodicalIF":1.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}